In total, 6.4% of participants had mpox antibodies, including 4% of cis women, 7% of cis men with only cis women partners, and 9% of men who have sex with men.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
COVID-19 vaccination may protect pregnant women and their fetuses against virus-related placentitis (inflammation of the placenta) and stillbirth, concludes a review study published today in the American Journal of Obstetrics & Gynecology. The research will also be presented next week at ID Week in Washington, DC.
The researchers were able to isolate infectious virus from 2 samples, including an air sample.
Of 219 patients, 216 (99%) reported sexual or close intimate contact in the 21 days before symptom onset.
Disparities still persist in disease burden, as well as monkeypox vaccine reach.
In its latest weekly update on the pandemic, the World Health Organization (WHO) said today that global COVID-19 cases declined 6% last week compared to the previous week, though the pace of activity increased in the European region, which experienced an 8% rise compared to the week before.
An expert points out, however, that the study didn't adust for risk factors like the number of sex partners.
Studies detail viral prevalence in various specimens and tattoo- and healthcare-related spread.
Retrospective UK testing reveals a case on Mar 7, two months earlier than previously reported.
According to a new non-peer reviewed study out of Israel, the Jynneos vaccine is 79% effective against monkeypox infection.
The study was based on patients eligible for monkeypox vaccine seen in the Clalit Health Services system between Jul 31 and Sep 12, 2022. Of 1,970 subjects eligible for the study, 873 (44%) were vaccinated with Jynneos and completed at least 25 days of follow-up.
Steady drops in new cases continue in North America and Europe, resulting in a 22% overall decline.